Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design.

by Esther Drent, Renée Poels, Manon J Mulders, Niels W C J van de Donk, Maria Themeli, Henk M Lokhorst, Tuna Mutis
Published 2018-01-01

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma

by Renée Poels, Esther Drent, Roeland Lameris, Afroditi Katsarou, Maria Themeli, Hans J. van der Vliet, Tanja D. de Gruijl, Niels W.C.J. van de Donk, Tuna Mutis
Published 2021-01-01

αβ-T Cells Engineered to Express γδ-T Cell Receptors Can Kill Neuroblastoma Organoids Independent of MHC-I Expression

by Josephine G. M. Strijker, Ronja Pscheid, Esther Drent, Jessica J. F. van der Hoek, Bianca Koopmans, Kimberley Ober, Sander R. van Hooff, Waleed M. Kholosy, Annelisa M. Cornel, Chris Coomans, Andrea Bisso, Marleen M. van Loenen, Jan J. Molenaar, Judith Wienke
Published 2021-09-01